Immunohistochemical Expression of HBME-1 in a Spectrum of Thyroid Neoplasms.

ABSTRACT:

Introduction

Thyroid neoplasms are the most common malignancy of the endocrine system, representing 3.8% of new cancer cases, and it is the ninth most common cancer overall. The immuno-histochemical marker Hector Battifora Mesotheilial-1 (HBME-1) is a monoclonal antibody that now finds its diagnostic utility as a positive marker for well-differentiated thyroid carcinomas. The aim was to study the expression of HBME-1 and to differentiate between malignant and non-malignant lesions by demonstrating their usefulness in the categorisation of thyroid neoplasms.

Methods

A prospective study was conducted at a tertiary care centre from August 2022 to May 2023, comprising 25 cases. All thyroidectomy specimens were included. They were subjected to histopathological examination using

SUBMITTER: Chawla AA 

PROVIDER: S-EPMC11774410 | biostudies-literature | 2024 Nov-Dec

REPOSITORIES: biostudies-literature